ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

IMFINZI
Bladder, kidney, and other urologic cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

IMFINZI Rx

Generic Name and Formulations:
Durvalumab 50mg/mL; soln for IV infusion after dilution; preservative-free.

Company:
AstraZeneca Pharmaceuticals

Therapeutic Use:

Indications for IMFINZI:

Locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Adult:

Give as IV infusion over 60mins. 10mg/kg every 2 weeks until disease progression or unacceptable toxicity.

Children:

Not established.

Warnings/Precautions:

Monitor for immune-related pneumonitis, hepatitis (obtain LFTs each cycle), colitis/diarrhea, endocrinopathies (thyroid disorders, adrenal insufficiency, diabetes, hypophysitis/hypopituitarism), rash, nephritis, others; see full labeling for adverse reaction management details. Permanently discontinue if Grade 3/4 pneumonitis, AST or ALT >8×ULN or total bilirubin >5×ULN, concurrent AST or ALT >3×ULN and total bilirubin >2×ULN (with no other cause), Grade 3/4 colitis or diarrhea, creatinine >3×ULN, Grade 3/4 infusion-related reactions, Grade 4 rash/dermatitis, other Grade 4 immune-mediated reactions, persistent Grade 2/3 reactions (except endocrinopathies), recurrent Grade 3/4 reactions, or inability to reduce to ≤10mg/day prednisone or equivalent. Withhold for Grade 2 pneumonitis, AST or ALT >3–8×ULN or total bilirubin >1.5–5×ULN, Grade 2 colitis or diarrhea, Grade ≥2 hypophysitis/hypopituitarism, Grade ≥2 adrenal insufficiency, Grade ≥2 hyperthyroidism, Grade ≥2 type 1 diabetes, creatinine >1.5–3×ULN, Grade 3/4 infection, Grade 2 (if >1 week) or Grade 3 rash. Monitor for signs/symptoms of infection. Interrupt or slow the infusion rate in patients with mild or moderate infusion reactions. Evaluate for Vogt-Koyanagi-Harada syndrome if uveitis in combination with other immune-mediated reactions occur. Embryo-fetal toxicity. Pregnancy. Females of reproductive potential should use effective contraception during therapy and for ≥3 months after final dose. Nursing mothers: not recommended (during and for ≥3 months after final dose).

Pharmacological Class:

Programmed death-ligand 1 (PD-L1) blocking antibody.

Adverse Reactions:

Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, UTI, cough, upper RTI, dyspnea, rash; other immune-related reactions (eg, aseptic meningitis, hemolytic anemia), infusion-related reactions, lab abnormalities.

Generic Availability:

NO

How Supplied:

Single-dose vial (2.4mL, 10mL)—1

Indications for IMFINZI:

Unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed after concurrent platinum-based chemotherapy and radiation.

Adult:

Give as IV infusion over 60mins. 10mg/kg every 2 weeks until disease progression, unacceptable toxicity, or max 12 months.

Children:

Not established.

Warnings/Precautions:

Monitor for immune-related pneumonitis, hepatitis (obtain LFTs each cycle), colitis/diarrhea, endocrinopathies (thyroid disorders, adrenal insufficiency, diabetes, hypophysitis/hypopituitarism), rash, nephritis, others; see full labeling for adverse reaction management details. Permanently discontinue if Grade 3/4 pneumonitis, AST or ALT >8×ULN or total bilirubin >5×ULN, concurrent AST or ALT >3×ULN and total bilirubin >2×ULN (with no other cause), Grade 3/4 colitis or diarrhea, creatinine >3×ULN, Grade 3/4 infusion-related reactions, Grade 4 rash/dermatitis, other Grade 4 immune-mediated reactions, persistent Grade 2/3 reactions (except endocrinopathies), recurrent Grade 3/4 reactions, or inability to reduce to ≤10mg/day prednisone or equivalent. Withhold for Grade 2 pneumonitis, AST or ALT >3–8×ULN or total bilirubin >1.5–5×ULN, Grade 2 colitis or diarrhea, Grade ≥2 hypophysitis/hypopituitarism, Grade ≥2 adrenal insufficiency, Grade ≥2 hyperthyroidism, Grade ≥2 type 1 diabetes, creatinine >1.5–3×ULN, Grade 3/4 infection, Grade 2 (if >1 week) or Grade 3 rash. Monitor for signs/symptoms of infection. Interrupt or slow the infusion rate in patients with mild or moderate infusion reactions. Evaluate for Vogt-Koyanagi-Harada syndrome if uveitis in combination with other immune-mediated reactions occur. Embryo-fetal toxicity. Pregnancy. Females of reproductive potential should use effective contraception during therapy and for ≥3 months after final dose. Nursing mothers: not recommended (during and for ≥3 months after final dose).

Pharmacological Class:

Programmed death-ligand 1 (PD-L1) blocking antibody.

Adverse Reactions:

Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, UTI, cough, upper RTI, dyspnea, rash; other immune-related reactions (eg, aseptic meningitis, hemolytic anemia), infusion-related reactions, lab abnormalities.

Generic Availability:

NO

How Supplied:

Single-dose vial (2.4mL, 10mL)—1

Sign Up for Free e-Newsletters